Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions
Mené sur 2 840 patientes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie invasive, et la toxicité du nératinib, un inhibiteur irréversible pan-HER, dispensé pendant un an après une thérapie adjuvante à base de trastuzumab (durée médiane de suivi : 5,2 ans)
In 2006, the US Food and Drug Administration (FDA) approved trastuzumab for the treatment of patients with early-stage HER2-positive breast cancer. Clinical trials have confirmed that trastuzumab-based chemotherapy significantly reduces the risk of disease recurrence and improves survival.1,2 We know that the optimal duration of treatment is 1 year, and that trastuzumab is more efficacious when administered concomitantly with chemotherapy;3 however, efforts to further improve the outcomes of these patients with new drugs have been somewhat disappointing.
The Lancet Oncology , commentaire, 2016